For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Budesonide - Inflammatory bowel disease
PAD Profile : Budesonide - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 3.
- Foam enema
Status 2 of 3.
- Modified release capsules
Status 3 of 3.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Tofacitinib
- Methotrexate
- Mesalazine (Systemic)
- Filgotinib
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Other Indications
- Oesophagitis (inducing remission)
- Oesophagitis (maintenance)
- Covid-19
- Nephropathy
- Asthma
- Bronchopulmonary dysplasia
Additional Documents
Committee Recommendations
Please see the attached pathway which has been developed in conjunction with local specialists for the GP management of adult patients with known ulcerative colitis .
Budesonide SUPPOSITORIES: have not yet been assessed for formulary status and is not currently on the APC work-plan.
This formulation has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.